Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm seriously considering buying into this and looking to get through the fluff and see if anyone can confirm what my research is telling me. Saying it's going to be worth billions or 10x in a year before proof of being able to make the drug and human trials is just pumping. I bought shares of a similar company that's much further along and has a much lower market cap so I'm skeptical. But I do like InMed's new management, associations and ability to raise funds.
10x in a year before they can show they can make their drugs to FDA standards and before human trials?
The CEO said it would be mid-2018 for the EB drug at the earliest so most likely 2 years with the patent still pending. The glaucoma drug is further out.
They're glaucoma drug is 3 years from human trials.
They filed patent applications 2 years ago so it will be another 6 months before they get an answer which means they'll start human trials in 18 months to 2 years if all goes well.
OWCP will not get on the NASDAQ selling a drug that's illegal in the US. They don't have patents yet and they would need at least a $10 million raise and a reverse split. NASDAQ isn't happening so let's stick to what this is. A company that has a promising cannabis cream that may be able to generate good revenue. OWCP is a cannabis company and not a biotech company yet.
They state they filed patent applications in the US 2 years ago. What's the status of those? They still need to be able to show they can make their leading drug candidate to FDA standards before they can ever start trials. They're at least 18 months out on that as the CEO admits and assuming it goes well. Their glaucoma candidate is years out.
An uplist to NASDAQ will require at least a $10 million raise and secured patents to develop cannabinoid drugs not cannabis drugs. They would not be able to sell their cream in the US if they want to get on the NASDAQ because it's illegal.
When it comes out, it won't be a FDA approved drug. To sell it in the US they will have a manufacturer/distributor in each state where it's legal. They won't be able to advertise it either so it will be word of mouth. If the drug is made from the plant and is not synthetic, it will never receive FDA approval unless they change policy.
I don't understand the comparison. They're not selling or planning on selling a drug in the US that is considered Federally illegal. They could manufacture and sell Sativex in each legal state but they know better.
NASDAQ seems very unlikely if they're selling a drug not FDA approved and considered illegal under Federal law.
Now that makes sense. What is IRB?
Marijuana that's not synthetic and approved as a drug by the FDA cannot be imported into the US and can't be shipped across state lines and they cannot advertise it as a psoriasis drug. It would be no different if their cream worked and contained 3% heroin. That's what I'm trying to get around. How will they manufacture it and distribute it in the US and broadly market it under current Federal law?
I'm thinking about pulling the trigger on this one but I'm concerned about the cream in the US. My understanding is they can't import it so it would have to be manufactured in each state they sell it and that they can't advertise it as a psoriasis cream because it's a drug not approved by the FDA. If true, how would they be able to advertise it and how and where would they manufacture it? Also, is the cream what everyone is betting on to drive the price up in the near future? Thank you to anyone who can answer.
Well said. This comes down to raising funds or securing a development deal. They have the IP so can they find the right partner to move this along? They have a great management group so I think they will.
It's frustrating to see other companies in the sector with much higher caps but that's because they cloud their narratives. They put out way more press that sounds good and makes companies sound more valuable than they are. I can't say with certainty but my take is IMLFF, OWCP, VBIO and a couple of others are most similar in that group. It's almost a complete guess what these companies are worth so people accept or justify the stock trends as the price goes up. I know with certainty IMLFF isn't more valuable than Nemus and it's at 5 times the cap. I know this because they are the most similar to Nemus in what they're trying to do. They tout a biosynthesis process that doesn't use chemicals that hasn't been proven yet while Nemus is already making one of their drugs using a similar process. They've talked about filing patents for 2 of their drugs for 2 years but nobody can find provisional patent numbers. Nemus has multiple, valuable patents and has proven it can make one of their drugs to FDA standards which can take years and they will prove they can make their glaucoma drug this year. IMLFF says they have a glaucoma drug they're working on but there's no patent yet. All this is ignored in the stock prices. They should be flip flopped.
So all this gets ignored and IMLFF sits at a 5x higher cap and we have some idiot on this board who is saying Nemus is the scam. LOL. Nemus is a straightforward no bs company. That's why the price drops or doesn't move. There's no fluff to get people irrationally excited. They don't seem to care about the retail investor so the price sits unless there's some news. Nemus won't be on the cannabis ETF that's coming out. They should be as 90% of the stocks in it will be pure garbage. Retail investors aren't flocking to Nemus because they don't try to attract them and they don't pump the stock at all. Perhaps they should because this should be above $1 for sure based on the market. Those of us that know what Nemus has will hold and ride it out as they secure funding. When they do, this company will probably be worth more than all of them at some point. If they don't, theyl'll sell the IP for $30-$40 million and call it a day. That's the bet as I see it.
1990- with all due respect, OWCP will not be able to import their cream into the US. The reason being is it does not meet FDA guidelines because it will contain THC that is a controlled substance. It would be no different if someone came up with a psoriasis cream that had 3% heroin in it. It would violate Federal law. All drugs or substances that come from marijuana or the poppy are considered Schedule I controlled substances and are illegal in the US unless they are in synthetic form and approved by the FDA. Non-approved drugs cannot be imported or shipped across state lines.
The only way GW will be able to import Epidilolex is if it receives FDA approval. Currently it cannot import Sativex even though it has gone through much more exhaustive studies than the OWCP cream ever will and is approved in many countries.
Nemus, Zynerba, GW and a couple others are working on drugs that will go through the FDA process and be approved as Schedule II-IV synthetic drugs that will be regulated like prescription narcotics. They can be imported and shipped across state lines. They are considered cannabinoid drugs and anything that does not meet those standards are considered cannabis and classified as Schedule I drugs and illegal Federally.
OWCP will have to make their cream in the states where it's legal and must sell within those states. They can't make it in Colorado and ship it to Washington even thought it's legal in both those states. A company just got busted for that by the DEA. They may leave medical MJ alone in approved states for the most part but they will hammer those who cross state lines and those who advertise their non-FDA approved drugs.
There are a few reasons why I wonder if their cream can be successful in the US. One is they have to have manufacturing in each legal state in the US that will include employees, benefits, shipping, sales reps etc. so that will be costly. Then they will have lots of competition as what they're doing can be easily replicated without violating their patent. Their patent doesn't really provide much protection because anyone can make what they're making and vary it slightly. There are small groups providing creams and all sorts of other cannabis variations for all types of ailments. People know people who can provide anything to meet their needs now so I'm not sure if a large, national company can have enough penetration. I'm not convinced there will be brand loyalty. OWCP and others will not be able to advertise their drug for psoriasis without FDA approval so it will be word of mouth. That's huge! Finally, once drugs start getting approved by the FDA, these non-FDA companies will go out of business because their products will be more expensive as insurance companies will only reimburse for FDA approved drugs and doctors are only going to prescribe approved drugs just for liability reasons alone.
There is a short window for these cannabis companies to make money until the FDA approved drugs kick in and there's tons of competition now so it's hard to guess who will be successful for that short run. I think the smaller, regional groups will do better than these large cannabis companies because they will have lower costs and regional loyalty through word of mouth. Just my opinion.
They spent $1 million on R&D which is more than any other cannabinoid company by far not named Zynerba, GW and a couple other established pharma companies.
They had about $1 million in salaries and office expenses. According to filings, no shares of stock were issued to insiders in 2016. Read that again. NO shares were issued to insiders in 2016 so again you have no clue what you're talking about. Care to share with us what the other $2.5 million in expenses were for since it didn't go to insiders or do you just want to continue to talk out of your ass?
The best comparisons to Nemus are InMed, VBIO and OWCP. However, Nemus has much better IP and more cash and are much further along in their cannabinoid drugs. Those companies have market caps 5 to 10 times higher than Nemus. There's no way this goes subpenny unless they can't raise any more funds. In the unlikelihood that happens, they can sell the IP for a higher valuation than the current price. It's ridiculous this company has a lower valuation than the others I mentioned. This company is way undervalued compared to the market.
You're so smart, explain what this is and I'll let you know if you're right. And then explain how Nemus is a stock selling scheme with proof.
Yes. Nemus is a cannabinoid company like Zynerba and GW and what InMed claims to be. Just to show you how undervalued Nemus is with a market cap of $7 million, InMed has a cap of $35 million with no patents that I could find and no proof they can make any of their drug candidates. Nemus has multiple worldwide patents and has proven they can make their leading drug candidate to FDA standards and will prove another one this year. There are only 4 or 5 companies in the world who have done that with cannabinoid drugs because it takes time and is expensive. InMed claims that they use a biosynthesis process while everyone else uses the plant which is totally false. Nemus uses biosynthesis for their drugs. Yet InMed has 5 times the market cap. I believe Nemus has the lowest market cap of any company in this sector which is insane. The price should easily be at $2 per share now just based on the value of the patents and the fact they can make their drug and will be able to fast track it.
I believe OWCP has a drug derived from cannabis that contains THC. They are not going through the FDA process which means they cannot make any medicinal claims Nemus, Zyne and GW are going through the FDA process and can when approved.
OWCP states they have drugs in the works that will go through the FDA process but their cream wiont be very well protected in the U.S.
You can post to your little hearts content but it doesn't change the facts. Everyone in management is wealthy and well respected with great track records, There have been no insider sales and literally no pumping of the stock. They are partnered with a respected research university who leads in cannabinoid research and could have partnered with anyone. They have patents that 99% of the companies in this sector don't have and they have proven they can make their l adding drug candidate to FDA standards. Look who they have contracted with to make their drugs. Those companies don't work with scammers. There is literally no evidence they aren't anything but legit and you've never provided any type of evidence other than to throw words out. So now your proof is a 13g of 120,000 shares? Do you really think anyone in management or the university profited from that?
If you keep going on this then you either have a personal agenda or lack intellectual honesty. I asked you to lay out proof this is a scam and you can't so go post to yourself on your Gardener board.
Just looked at your Gardeners Diary Board you moderate where only you post to yourself and nobody else posts and it's actually sad. It's clear you're completely uninformed about Nemus and this will be the last time I address your posts. Now I see why you make stuff up. Good luck.
If it has THC in it it's a drug.
I may be wrong but I don't think they will be able to advertise as a psoriasis drug or make any claims without FDA approval.
That's fine but it could never be marketed as such in the U.S. without FDA approval and it won't receive FDA approval in its current formulation. Therefore, it won't have an advantage in the U.S. to other similar products in my opinion.
How hard will it be for others to replicate a similar product?
Doubling down on stupid. The self-proclaimed pot stock sheriff who hides behind a keyboard and spews garbage. I hope your post isn't deleted so your stupidity can be here for all to see everyday. Detail how Nemis is a scam or did someone from Nemus steal your girlfriend/boyfriend?
Itemize your points on why it's a scam from all your brilliant "due diligence" or run along to the other boards that really are scams. Make sure you include your theory on how a preiminent public research university is in on the scam.
Their cream is a cannabis play not a cannabinoid play and therefore fairly easily replicated. There will most likely be dozens of similar products available if it's allowed to be sold in the U.S.
You tout yourself to be the one who exposes all the scam marijuana stocks which isn't particularly hard because almost all are. But when you target a company like Nemus you lose all credibility. Nemus management consists of multi-millionaires who have devoted their time and expertise without making a penny since the company started. There has been no insider sales and not one penny has been spent on pumping the stock. In fact Nemus has too low a profile. They have valuable patents and continue to develop their drug candidates. They may or may not execute but this is a legit company. I'm not sure you know the difference between cannabinoid companies and cannabis companies but there is a difference. There are probably 5 legit cannabinoid companies and Nemus is one of them.
If you want to target some scam cannabinoid companies then check out InMed who just spent $100k on pumping and has for 2 years said they are filing patents yet there's no patent numbers that you get even for provisionals. They claim they have a biosynthesis process while everyone else uses the plant when nobody in cannabinoids are using the plant. There's also OWCP and VBIO that don't have anything.
For cannbis stocks check out CBDS whose price is at $6 with no money, no revenue and tons of insider sales.
If you try to blanket Nemus you'll look like an idiot. I gave you a list of scam stocks so go have fun with them.
Patent numbers. I've invested in a couple cannabinoid companies and really want to add this as the final one but I haven't been able to find patent numbers on anything they've said they've filed patents on the past 2 years. Can anyone find patent numbers which are critical to the value of this company?
https://www.newcannabisventures.com/israeli-cannabinoid-biotech-therapix-ipos-on-nasdaq/
Checked out what Therapix has compared to Nemus and it's not close. Hard to believe Therapix is able to get this done based on their IP and target indications. Nemus management should be able to execute something similar or work out partnerships. Seeing what Therapix is doing should give everyone hope that Nemus is headed for much bigger and better things.
http://www.in-pharmatechnologist.com/Ingredients/Teewinot-patents-biosynthesis-for-cannabinoids
Teewinot is not using chemical synthesis.
Thank you I saw these before, I just don't get the point of it as any serious company developing cannabinoids is not extracting from the plant. They're using biosynthesis. Maybe InMed has a better technology but there's no way of knowing if their PR compares it to plant extraction that nobody is doing.
Teewinot is doing biosynthesis for several companies which is cost effective and fast. Other than GW, nobody is going to develop a drug using the plant. It won't get approved for one and it's too costly and inefficient for another. It seems that InMed is doing it differently but I have no idea if it's better or cheaper or faster. Perhaps others can shed light on it.
InMed intrigues me because there could be something there. I just can't tell if what they have has value. They're probably 2 years away from being able to make their drug and don't have any approved patents yet from what I can tell.
By my estimation, Nemus is about 2 years ahead of InMed in glaucoma and their other drug candidate is about a year ahead of their glaucoma candidate. In comparison, the differences seem to be that Nemus already has several patents, they've proven they can make their leading drug to FDA standards and are working on fast tracking it to approval. They are now working on proving they can make their glaucoma drug.
InMed has no patents yet that we know of and it will take them 2 years to prove they can even make their EB drug.
Nemus has 1/4 of the outstanding shares and their market cap is 4 times less than InMed's. It seems to me that should be flip flopped. I'm waiting to see if InMed has patents and trying to figure out what they have before I pull the trigger and buy. Everyone is doing biosynthesis now so not sure if InMed has anything there either.
It doesn't look like they have any patents. They announced they filed provisional patients in May 2015 for EB and glaucoma and there was never any news after that. They've never provided provisional patent numbers for any of their filings and now they announce they're filing a provisional patent for EB again and working on their glaucoma formulation. Nothing ever came from their 2015 filings so I have no idea what IP this company has or can even patent.
According to the CEO, they haven't shown they can make their leading drug candidate to FDA standards yet and it will take at least a year before they"ll know if they can. I haven't been able to find any proof of patents or provisional patents for their drug candidates either. Only that they've filed for them a couple of times over the past 2 years.
Questions regarding patents for their glaucoma and EB drugs. I've invested in a couple other cannabinoid companies and InMed is interesting as well. I've seen they've issued press releases that they filed provisional patents for both drug candidates in 2015 and then state again they are filing a provisional patent for EB again this year. What happened in 2015? Also, every biotech company I've researched provides patent numbers for their patents or provisional patents yet I can't find any patent numbers in InMed's regulatory filings. Can anyone shed light on this and if they've seen the patent or provisional numbers that would be issued?
Nemus presenting at Roth Capital Conference on Wednesday and Dr. Murphy in roundatable discussion tomorrow at 1. Should be able to watch it on the Roth webcast. InMed will be there too and has a market cap 4 times higher than Nemus. The Nemus group thinks they have better much better IP and are way ahead of them.
http://www.roth.com/main/page.aspx?PageID=7282